Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-10

Clinical Trial Update: Melatonin for Prevention of Post Stroke Delirium [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update on using melatonin to prevent post-stroke delirium across Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Melatonin (melatonin)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Post Stroke Delirium | Phase 2, Phase 3 | Status: UNKNOWN